First, the researchers compared 1,857 patients with severe AD who used dupilumab without any other systemic therapy (average age at dupilumab prescription, 28.54 years; 51.59% female; 49.81% white ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Dupilumab is injected subcutaneously from a single-dose prefilled syringe or a prefilled pen (syringe hidden in an opaque sheath), typically in the thigh, arm, abdomen, or buttocks.

• Dupilumab comes as a pre-filled syringe which has to be injected under the skin as a subcutaneous injection. • Before injecting dupilumab, it is necessary to allow the medication to come to ...

Your doctor will prescribe either a prefilled syringe or a pen with the correct dose in it. ... Dupilumab keeps your immune system from overreacting by targeting IL-4 and IL-13.

Dupilumab (Dupixent) achieves about a 50% reduction in itch and hive activity overall. ... It comes in a syringe or in a self-injector pen. It can be given by the patient at home or in the office.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children ...

Dupilumab is used along with topical corticosteroids or alone as a monotherapy. ... • Dupilumab comes as a pre-filled syringe which has to be injected under the skin as a subcutaneous injection.

Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's efficacy in children with atopic dermatitis and co ...

Dupilumab was also associated with improvements in lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 160mL vs 77mL for placebo; P <.0001) that were sustained through 52 ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and ...